First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: SELLAS Life Sciences: the story is balanced — Phase 3 REGAL trial data readouts for GPS in AML maintenance therapy - primary endpoint overall survival data expected…
momentum/speculative - The 198.4% one-year return and 138.4% three-month return reflect classic biotech momentum trading around binary…
Rising interest rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of future cash flows…
Watch on earnings: Phase 3 REGAL trial enrollment completion and data lock timing announcements, Quarterly cash burn rate and months of runway remaining before next financing event, FDA orphan drug designation expansions or breakthrough therapy designation applications.
One Sentence Summary:
SELLAS Life Sciences: the story is balanced — phase 3 regal trial data readouts for gps in aml maintenance therapy - primary endpoint overall survival data expected in 2026-2027.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.